GlassScriptPhysician profile
David Bryan Tanis
NPI 1598372807
$8,077.55
in general payments reported to CMS, 2019-2025
21 companies · $1,830 in 2025
The $1,830 reported for 2025 was more than what 91% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $175 · 2022: $1,538 · 2023: $1,787 · 2024: $2,748 · 2025: $1,830.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,340 · Education: $24.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,340.48 |
| Education | $24.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,441.38 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $1,272.60 | 2022-2025 | Ingrezza |
| Abbvie INC. | $1,253.32 | 2022-2025 | |
| Corium, LLC | $491.02 | 2022-2025 | Azstarys |
| Alkermes, INC. | $485.52 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Lundbeck LLC | $480.14 | 2023-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $474.34 | 2021-2025 | Rexulti, Nuedexta, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $428.99 | 2022-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $323.64 | 2023-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $307.01 | 2022-2024 | Trintellix |
| Supernus Pharmaceuticals, INC. | $306.94 | 2022-2025 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $167.67 | 2022-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Indivior INC. | $125.52 | 2023-2025 | Sublocade |
| Janssen Scientific Affairs, LLC | $117.33 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $102.34 | 2022-2025 | Austedo Xr, Uzedy, Austedo Xr |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $78.63 | 2024-2025 | Cobenfy |
| Avanir Pharmaceuticals, INC. | $75.86 | 2022 | |
| Idorsia Pharmaceuticals US INC | $52.63 | 2023-2025 | Quviviq, Quviviq |
| Harmony Biosciences LLC | $52.48 | 2024 | |
| Almatica Pharma LLC | $26.84 | 2022 | |
| Ironshore Pharmaceuticals INC. | $13.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Tanis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.